|
業務類別
|
Biotechnology |
|
業務概覽
|
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed tohave a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. |
| 公司地址
| 323 Allerton Avenue, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 466-7125 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.alxoncology.com |
| 員工數量
| 43 |
| Mr. Jeff E. Knight |
Chief Development Officer and Chief Operating Officer |
-- |
13/04/2026 |
| Mr. Harish Shantharam |
Chief Financial Officer |
美元 464.48K |
20/04/2026 |
| Ms. Shelly Wong |
Senior Vice President, Finance and Chief Accounting Officer |
美元 435.59K |
20/04/2026 |
| Mr. Jason Lettmann |
Chief Executive Officer and Director |
美元 724.50K |
20/04/2026 |
| Ms. Shelly Pinto |
Senior Vice President, Finance and Chief Accounting Officer |
-- |
09/03/2026 |
| Dr. Barbara Klencke, M.D. |
Chief Medical Officer |
-- |
20/04/2026 |
|
|
| Dr. Corey S. Goodman,PhD |
Chairman of the Board |
20/04/2026 |
| Dr. Chris H. Takimoto, F.A.C.P. |
Independent Director |
20/04/2026 |
| Dr. Alan B. Sandler, M.D. |
Director |
20/04/2026 |
| Mr. Scott Garland |
Independent Director |
20/04/2026 |
| Mr. Jason Lettmann |
Chief Executive Officer and Director |
20/04/2026 |
| Dr. Daniel Curran, M.D. |
Independent Director |
20/04/2026 |
| Ms. Rekha Hemrajani, M.B.A. |
Independent Director |
20/04/2026 |
|
|
|
|
